Zura Bio Limited (NASDAQ:ZURA) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Zura Bio Limited (NASDAQ:ZURA) have earned an average rating of “Moderate Buy” from the six brokerages that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $10.75.

A number of brokerages have commented on ZURA. Oppenheimer dropped their price objective on shares of Zura Bio from $16.00 to $15.00 and set an “outperform” rating on the stock in a research report on Friday, March 20th. Chardan Capital increased their price objective on shares of Zura Bio from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, March 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a research report on Wednesday, April 8th. Finally, Wedbush began coverage on shares of Zura Bio in a research report on Monday, February 9th. They issued an “outperform” rating and a $15.00 price objective on the stock.

Zura Bio Stock Down 3.3%

Zura Bio stock opened at $4.10 on Wednesday. The firm has a market cap of $389.01 million, a PE ratio of -3.76 and a beta of 0.03. Zura Bio has a 52-week low of $0.99 and a 52-week high of $7.44. The company’s 50 day moving average is $5.18 and its two-hundred day moving average is $5.25.

Zura Bio (NASDAQ:ZURA) last released its earnings results on Thursday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). On average, equities research analysts anticipate that Zura Bio will post -0.73 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zura Bio

Large investors have recently modified their holdings of the company. Atika Capital Management LLC purchased a new stake in shares of Zura Bio in the 3rd quarter valued at approximately $1,195,000. Suvretta Capital Management LLC increased its position in shares of Zura Bio by 12.6% in the 3rd quarter. Suvretta Capital Management LLC now owns 5,472,891 shares of the company’s stock valued at $23,698,000 after purchasing an additional 611,952 shares during the last quarter. Boothbay Fund Management LLC purchased a new stake in shares of Zura Bio in the 3rd quarter valued at approximately $3,568,000. UBS Group AG increased its position in shares of Zura Bio by 54.1% in the 4th quarter. UBS Group AG now owns 470,540 shares of the company’s stock valued at $2,466,000 after purchasing an additional 165,211 shares during the last quarter. Finally, Barclays PLC increased its position in shares of Zura Bio by 2,432,950.0% in the 4th quarter. Barclays PLC now owns 48,661 shares of the company’s stock valued at $255,000 after purchasing an additional 48,659 shares during the last quarter. 61.14% of the stock is owned by hedge funds and other institutional investors.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.